{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:37:59Z","timestamp":1784043479186,"version":"3.55.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder. This review summarizes its current therapeutic uses and potential advantages for treating the main symptoms of schizophrenia, bipolar I and major depressive disorder, considering its pharmacodynamic properties, efficacy, and tolerability. Its predominantly D3 receptor preferring affinity, with functional selectivity according to the prevailing neuronal environment, contributes to its efficacy across a wide array of psychopathological symptoms (including reality distortion, disorganized thought, negative symptoms, mood disturbance, anhedonia, and cognitive impairment), and to a favorable side effect profile. Cariprazine may be a \u201cdrug of choice\u201d in patients with predominant negative and cognitive symptoms of schizophrenia, as well as those with metabolic syndrome. Further investigation of its relative efficacy when compared to aripiprazole or other active comparators is warranted. Its effectiveness in the treatment of bipolar mania, bipolar I depression and bipolar I episodes with mixed features, with minimal accompanying metabolic changes is well-established. The longer half-life and delayed time to relapse in patients diagnosed with schizophrenia when compared to other second-generation antipsychotics represent other advantages, given the high rates of non-adherence and frequent relapses seen in clinical practice. Its efficacy in overlapping symptom domains in other major psychiatric disorders appears promising.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.784370","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:47:25Z","timestamp":1638272845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3\/D2 Preferring Partial Agonist Cariprazine"],"prefix":"10.3389","volume":"12","author":[{"given":"Borjanka","family":"Batinic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Ristic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Zugic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.4088\/JCP.1006e12","article-title":"Cognitive impairment and functional outcome in schizophrenia and bipolar disorder","volume":"67","author":"Green","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.08m04837yel","article-title":"Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum","volume":"71","author":"Jabben","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31219\/osf.io\/ju6vs","article-title":"Assessment of 21qcognitive function, social disability and basic life skills in euthymic patients with bipolar disorder","volume":"33","author":"Batinic","year":"2021","journal-title":"Psychiatr Danubina"},{"key":"B4","first-page":"59","article-title":"Evidence for shared susceptibility in bipolar disorder and schizophrenia","volume-title":"Am J Med Genet","author":"Berrettini","year":"2003"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/archpsyc.60.12.1209","article-title":"Individual and familial risk factors for bipolar affective disorders in Denmark","volume":"60","author":"Mortensen","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"B6","first-page":"48","article-title":"Family, twin, and adoption studies of bipolar disorder","volume-title":"Am J Med Genet C Semin Med Genet.","author":"Smoller","year":"2003"},{"key":"B7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(09)60072-6","article-title":"Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study","volume":"373","author":"Lichtenstein","year":"2009","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-clinpsy-032814-112915","article-title":"Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder","volume":"11","author":"Pearlson","year":"2015","journal-title":"Annu Rev Clin Psychol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0021-5198(19)46541-4","article-title":"Pharmacological profile of OPC-14597, a novel antipsychotic drug (1): Presynaptic dopamine autoreceptor agonistic activity and postsynaptic dopamine D2 receptor antagonistic activity","volume":"67","author":"Kikuchi","year":"1995","journal-title":"Jpn J Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1744-6163.2002.tb01566.x","article-title":"Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?","volume":"38","author":"Keltner","year":"2002","journal-title":"Perspect Psychiatr Care."},{"key":"B12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist\u2013partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr Pharm Design."},{"key":"B15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature."},{"key":"B16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1124\/jpet.119.259879","article-title":"The role of dopamine D3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens","volume":"371","author":"Huang","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B17","unstructured":"2021"},{"key":"B18","unstructured":""},{"key":"B19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Design Dev Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4172\/2161-1459.1000117","article-title":"The pharmacological role and clinical applications of antipsychotics' active metabolites: paliperidone versus risperidone","volume":"3","author":"\u00c1lamo","year":"2013","journal-title":"Clin Exp Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2147\/NDT.S210340","article-title":"Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation","volume":"15","author":"Correll","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B23","unstructured":"2021"},{"key":"B24","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B25","first-page":"638","article-title":"Schizophrenia: overview and treatment options.P T","volume":"39","author":"Patel","year":"2014"},{"key":"B26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"18m12495","DOI":"10.4088\/JCP.18m12495","article-title":"Long-term remission with cariprazine treatment in patients with schizophrenia","volume":"80","author":"Correll","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomized, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/YIC.0000000000000351","article-title":"The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study","volume":"36","author":"Rancans","year":"2021","journal-title":"Int Clin Psychopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1016\/j.euroneuro.2020.09.421","article-title":"P.575 Long-term functional improving effects of cariprazine: post-hoc analyses of acute and predominant negative symptom schizophrenia patient data","volume":"40","author":"Laszlovszky","year":"2020","journal-title":"Eur Neuropsychopharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12888-018-1755-2","article-title":"Functional recovery in patients with schizophrenia: recommendations from a panel of experts","volume":"18","author":"Lahera","year":"2018","journal-title":"BMC Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"MS19053BR2C","DOI":"10.4088\/JCP.MS19053BR2C","article-title":"Using patient-centered assessment in schizophrenia care","volume":"81","author":"Correll","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/TCRM.S35137","article-title":"A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia","volume":"9","author":"Caccia","year":"2013","journal-title":"Ther Clin Risk Manag."},{"key":"B41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther Adv Psychopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.9758\/cpn.2021.19.1.174","article-title":"Cariprazine add-on in inadequate clozapine response: a report on two cases","volume":"19","author":"de Berardis","year":"2021","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12991-020-00305-3","article-title":"Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel","volume":"19","author":"Fagiolini","year":"2020","journal-title":"Ann Gen Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1399-5618.2011.00935.x","article-title":"Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables","volume":"13","author":"Mann-Wrobel","year":"2011","journal-title":"Bipolar Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4088\/JCP.13r08609","article-title":"Cognitive Effects of pharmacotherapy for major depressive disorder","volume":"75","author":"Keefe","year":"2014","journal-title":"J Clin Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.psychres.2016.12.031","article-title":"Neuropsychological profiles of major depressive disorder and bipolar disorder during euthymia. A systematic literature review of comparative studies","volume":"248","author":"Szmulewicz","year":"2017","journal-title":"Psychiatry Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.psychres.2018.02.025","article-title":"Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia","volume":"263","author":"Sum","year":"2018","journal-title":"Psychiatry Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jad.2007.12.234","article-title":"Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up","volume":"109","author":"Tabar\u00e9s-Seisdedos","year":"2008","journal-title":"J Affect Disord."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0924-9338(10)71417-6","article-title":"PW01-15- Neurocognitive function in clinically stable patients with bipolar disorder or schizophrenia and normal controls","volume":"25","author":"Konstantakopoulos","year":"2010","journal-title":"Eur Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ajp.2013.02.001","article-title":"Schizophrenia patients experience substantial social cognition deficits across multiple domains in remission","volume":"6","author":"Mehta","year":"2013","journal-title":"Asian J Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","article-title":"Neurobiology of dopamine in schizophrenia","volume":"78","author":"Guillin","year":"2007","journal-title":"Int Rev Neurobiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/08039480903484076","article-title":"Extrapyramidal side-effects and dopamine D2\/3receptor binding in substantia nigra","volume":"64","author":"Tuppurainen","year":"2010","journal-title":"Nordic J Psychiatry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","article-title":"Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse","volume":"226","author":"Zimnisky","year":"2013","journal-title":"Psychopharmacology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.euroneuro.2015.11.016","article-title":"Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology","volume":"26","author":"Neill","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/S1092852917000608","article-title":"Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"B56","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2174\/1871527316666170728165355","article-title":"New trends in the treatment of schizophrenia","volume":"16","author":"Meltzer","year":"2018","journal-title":"CNS Neurol Disord"},{"key":"B57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S1092852917000426","article-title":"Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"B58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S109285291900083X","article-title":"The role of dopamine D3 receptors in the mechanism of action of cariprazine","volume":"25","author":"Calabrese","year":"2020","journal-title":"CNS Spectr."},{"key":"B59","first-page":"601","article-title":"Quality of life among patients with bipolar disorder","volume":"29","author":"Islam","year":"2020","journal-title":"Mymensingh Med J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2019.05.032","article-title":"Quality of life in euthymic bipolar patients: a systematic review and meta-analysis","volume":"255","author":"Pascual-S\u00e1nchez","year":"2019","journal-title":"J Affect Disord."},{"key":"B61","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40263-015-0275-6","article-title":"Diagnosis, epidemiology and management of mixed states in bipolar disorder","volume":"29","author":"Fagiolini","year":"2015","journal-title":"CNS Drugs."},{"key":"B62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.genhosppsych.2015.12.005","article-title":"Factors related to suicidal behavior in patients with bipolar disorder: the effect of mixed features on suicidality","volume":"39","author":"Seo","year":"2016","journal-title":"Gen Hosp Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder","volume":"76","author":"Calabrese","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"B65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, Phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J Affect Disord."},{"key":"B66","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jad.2019.07.020","article-title":"Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials","volume":"257","author":"McIntyre","year":"2019","journal-title":"J Affect Disord."},{"key":"B67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jad.2015.02.011","article-title":"Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders","volume":"178","author":"Forte","year":"2015","journal-title":"J Affect Disord."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am J Psychiatry."},{"key":"B69","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B70","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study","volume":"176","author":"Earley","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"20m02611","DOI":"10.4088\/PCC.20m02611","article-title":"Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications","volume":"22","author":"Yatham","year":"2020","journal-title":"Primary Care Companion CNS Disord"},{"key":"B72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/14737175.2019.1580571","article-title":"Cariprazine for the treatment of bipolar depression: a review","volume":"19","author":"Ragguett","year":"2019","journal-title":"Expert Rev Neurother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jad.2019.11.098","article-title":"A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression","volume":"263","author":"Earley","year":"2020","journal-title":"J Affect Disord."},{"key":"B74","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1017\/S1092852919001287","article-title":"Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies","volume":"25","author":"McIntyre","year":"2020","journal-title":"CNS Spectr."},{"key":"B75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.amjopharm.2006.12.007","article-title":"Treatments for late-life bipolar disorder","volume":"4","author":"Aziz","year":"2006","journal-title":"Am J Geriatr Pharmacother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.03.035","article-title":"Predominant polarity as a course specifier for bipolar disorder: a systematic review","volume":"163","author":"Carvalho","year":"2014","journal-title":"J Affect Disorders."},{"key":"B77","first-page":"108","article-title":"Suicide in bipolar disorder: a review","volume-title":"Psychiatr Danub.","author":"Latalova","year":"2014"},{"key":"B78","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/jpm11090865","article-title":"Emotional dysregulation, temperament and lifetime suicidal ideation among youths with mood disorders","volume":"11","author":"Janiri","year":"2021","journal-title":"J Pers Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/NDT.S100846","article-title":"Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review","volume":"12","author":"Fornaro","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.1198","article-title":"Where is the room for improvement in the drug treatment of depression and anxiety?","volume":"26","author":"Baldwin","year":"2011","journal-title":"Hum Psychopharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants","volume":"77","author":"Durgam","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B82","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low- dose cariprazine in major depressive disorder","volume":"33","author":"Fava","year":"2018","journal-title":"Int Clin Psychopharmacol."},{"key":"B83","first-page":"62","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley","year":"2018","journal-title":"Psychopharmacol Bull."},{"key":"B84","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs lithium","volume":"35","author":"V\u00e1zquez","year":"2021","journal-title":"J Psychopharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"555694","DOI":"10.19080\/GJIDD.2019.06.555694","article-title":"Cariprazine in autism spectrum disorder and intellectual disability disorder","volume":"6","author":"Cohen","year":"2019","journal-title":"Glob J Intellect Dev Disabil."},{"key":"B86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-012-2906-7","article-title":"Cariprazine (RGH-188), a D3-preferring dopamine D3\/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats","volume":"226","author":"Rom\u00e1n","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00213-021-05851-6","article-title":"Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder","volume":"238","author":"Rom\u00e1n","year":"2021","journal-title":"Psychopharmacology (Berl)."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.784370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:47:33Z","timestamp":1638272853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.784370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":87,"alternative-id":["10.3389\/fpsyt.2021.784370"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.784370","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"article-number":"784370"}}